QLogo_Primary_RGB_1000x843 (1).jpg
QIAGEN und International Panel Physicians Association fördern gemeinsam Bewusstsein für Tuberkulose-Screenings
March 18, 2024 16:05 ET | QIAGEN N.V.
Gemeinsame Bildungsinitiative konzentriert sich auf die Vorteile des Interferon-Gamma-Release-Assays (IGRA) für medizinisches Fachpersonal // Aktualisierte Richtlinien der US-amerikanischen CDC...
PRISM MarketView Spotlights Companies Leading the Charge in Liver Disease Treatment Following Landmark FDA Approval
PRISM MarketView Spotlights Companies Leading the Charge in Liver Disease Treatment Following Landmark FDA Approval
March 18, 2024 14:37 ET | PRISM MarketView
PRISM MarketView Spotlights Companies Leading the Charge in Liver Disease Treatment Following Landmark FDA Approval
ocugen_4C_LOGO (002).png
Ocugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical Officer
March 18, 2024 06:30 ET | Ocugen
MALVERN, Pa., March 18, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
First-Wave-Logo-FINAL-RGB[1].jpg
First Wave BioPharma Announces Completion of Business Combination with ImmunogenX, Adding Phase 3-Ready Latiglutenase to its Late-Stage GI-Focused Clinical Pipeline
March 14, 2024 06:00 ET | First Wave BioPharma, Inc.
Latiglutenase is a potentially first-in-class oral biotherapeutic for the treatment of celiac disease James Sapirstein, Chairman and Chief Executive Officer, to continue leading First Wave...
22157.jpg
3-Day Technical Writing Course for Professionals in the Life Sciences (Webinar: August 5-7, 2024)
March 14, 2024 05:43 ET | Research and Markets
Dublin, March 14, 2024 (GLOBE NEWSWIRE) -- The "Technical Writing Course for professionals in the Life Sciences" training has been added to ResearchAndMarkets.com's offering. This virtual seminar...
ocugen_4C_LOGO (002).png
Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410
March 13, 2024 08:00 ET | Ocugen
MALVERN, Pa., March 13, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
logo_ProQR-150x150.png
ProQR Announces Year End 2023 Operating and Financial Results
March 13, 2024 07:00 ET | ProQR Therapeutics N.V.
Preclinical and translational pipeline program data for AX-0810 for Cholestatic Diseases targeting NTCP and AX-1412 for Cardiovascular Disease targeting B4GALT1 anticipated in 2024, building further...
ADCT_4C_TM.png
ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
March 13, 2024 07:00 ET | ADC Therapeutics SA
ZYNLONTA® (loncastuximab tesirine-lpyl) net sales of $16.6 million in 4Q 2023 and $69.1 million for full year (FY) 2023; 4Q sales grew sequentially in both academic and community settings Focused...
cmi_logo.png
[Latest] Global Smart Healthcare Products Market Size/Share Worth USD 485.71 Billion by 2032 at a 12.78% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
March 12, 2024 12:30 ET | Custom Market Insights
Austin, TX, USA, March 12, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Smart Healthcare Products Market Size, Trends and Insights By Type (Wearable...
Astrocyte Logo.png
Astrocyte Pharmaceuticals Announces FDA Clearance of its Investigational New Drug Application for AST-004
March 12, 2024 12:00 ET | Astrocyte Pharmaceuticals
Astrocyte Pharmaceuticals Announces FDA Clearance of its Investigational New Drug Application for AST-004